» Articles » PMID: 22607078

Case Management and Supportive Treatment for Patients with Crimean-Congo Hemorrhagic Fever

Overview
Date 2012 May 22
PMID 22607078
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Crimean-Congo hemorrhagic fever (CCHF) is a tick-borne infection which has been increasing in Turkey and European countries since the year 2000. The disease is particularly endemic in the Middle East and in some African countries. It is also seen in European countries as a travel infection. Patients with confirmed diagnosis are usually hospitalized for monitoring, while patients with good overall condition may be monitored on an outpatient basis. Hospitals that manage CCHF should have easy access to a blood bank, and tertiary care hospitals must have a well-equipped intensive care unit. Strict blood and body fluid control precautions should be started on admission to limit CCHF exposure. The follow-up period for each patient is determined based on individual clinical status and laboratory values. Since there is no specific antiviral treatment for CCHF, supportive treatment is essential. This review highlights some of the major features of case monitoring and supportive treatment in CCHF.

Citing Articles

Detection of Crimean-Congo haemorrhagic fever virus in ticks, southern France, May 2022 and April 2023.

Bernard C, Joly Kukla C, Rakotoarivony I, Duhayon M, Stachurski F, Huber K Euro Surveill. 2024; 29(6).

PMID: 38333936 PMC: 10853980. DOI: 10.2807/1560-7917.ES.2024.29.6.2400023.


The Effect of Fetuin-A and Other Laboratory Paremeters on Prognosis and Mortality in Crimean-Congo Hemorrhagic Fever.

Demirci B, Coskun A Iran J Public Health. 2023; 52(1):97-105.

PMID: 36824242 PMC: 9941435. DOI: 10.18502/ijph.v52i1.11670.


The Relationship Between Cytokine Concentrations and Severity Scoring Index for Crimean-Congo Hemorrhagic Fever.

Onuk S, Sipahioglu H, Dursun Z, Eren E, Aslan Sirakaya H, Kuzuguden S Cureus. 2023; 15(2):e34882.

PMID: 36788994 PMC: 9922379. DOI: 10.7759/cureus.34882.


Development of a protective inactivated vaccine against Crimean-Congo hemorrhagic fever infection.

Berber E, Canakoglu N, Tonbak S, Ozdarendeli A Heliyon. 2021; 7(10):e08161.

PMID: 34703927 PMC: 8526982. DOI: 10.1016/j.heliyon.2021.e08161.


Development of a novel recombinant ELISA for the detection of Crimean-Congo hemorrhagic fever virus IgG antibodies.

Gulce-Iz S, Elaldi N, Can H, Atalay Sahar E, Karakavuk M, Gul A Sci Rep. 2021; 11(1):5936.

PMID: 33723328 PMC: 7961021. DOI: 10.1038/s41598-021-85323-1.